# AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib

> **NCT00467025** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 152 (actual)

## Conditions studied

- Advanced Renal Cell Carcinoma

## Interventions

- **DRUG:** AMG 386
- **DRUG:** Sorafenib
- **DRUG:** AMG 386 placebo IV

## Key facts

- **NCT ID:** NCT00467025
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2010-04
- **Final completion:** 2014-06
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2016-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00467025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00467025, "AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00467025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*